Pharmacologic Treatment of Chemotherapy-Induced Nausea and Vomiting

References

• Whitehead V M. Cancer treatment needs better antiemetics. N Engl J Med 1975; 293: 199–200 (letter)
   PubMed Web of Science ®Google Scholar
• Enck R E. Mallory-Weiss lesion following cancer chemotherapy. Lancet 1977; 2: 927–928
   PubMed Web of Science ®Google Scholar
• Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. Antiemetics and Cancer Chemotherapy, J Laszlo. Williams and Wilkins, Baltimore 1983; 2
   Google Scholar
• Penta J S, Poster D S, Bruno S. The pharmacologic treatment of nausea and vomiting caused by cancer chemotherapy: A review. Antiemetics and Cancer Chemotherapy, J Laszlo. Williams and Wilkins, Baltimore 1983
   Google Scholar
• Borison H L, McCarthy L E. Physiologic basis of nausea and vomiting. Treatment of Cancer Chemotherapy Induced Nausea and Vomiting, D S Poster, J S Penta, S Bruno. Masson Publishing, New York 1981; 33–34
   Google Scholar
• Borison H L, Wang S C. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193–230
   PubMed Web of Science ®Google Scholar
• Seigel L J, Longo D L. The control of chemotherapy induced emesis. Ann Intern Med 1981; 95: 352–359
   PubMed Web of Science ®Google Scholar
• Borison H L, McCarthy L E. Neuropharmacology of chemotherapy induced emesis. Drugs 1983; 25(Suppl)8–17
   PubMedGoogle Scholar
• Borison H L, Fairbanks V F. Mechanism of veratrum induced emesis in the cat. J Pharmacol Exp Ther 1952; 104: 317–325
   PubMedGoogle Scholar
• Borison H L, Harris T D, Schmidt A M. Central emetic action of pilocarpine in the cat. J Neuropath Exp Neurol 1956; 15: 485–491
   PubMed Web of Science ®Google Scholar
• Brand E D, Harris T D, Borison H L, et al. The antiemetic activity of 10 (r-dimethylaminopropyl) 2-chlorophenothiazine (chlorpromazine) in dog and cat. J Pharm Exp Ther 1954; 110: 86–92
   PubMed Web of Science ®Google Scholar
• Edmonds-Seal J, Prys-Roberts C. Pharmacology of drugs used in neuroleptanalgesia. Br J Anaesthesiol 1970; 42: 207–216
   PubMed Web of Science ®Google Scholar
• Justin-Besancon L, Laville C. Action antiemetic du me-toclopramide vis-a-vis de 1′apomorphine et de l'hydergine. CR Seances Soc Biol Paris 1964; 158: 723
   PubMedGoogle Scholar
• Borison H L, McCarthy L E. Neuropharmacologic mechanisms of emesis. Antiemetics and Cancer Chemotherapy, J Laszlo. Williams and Wilkins, Baltimore 1983
   Google Scholar
• Borison H L, Brand E D, Orkand R K. Emetic action of nitrogen mustard (mechlorethamine hydrochloride) in dogs and cats. Am J Physiol 1958; 192: 410–416
   PubMed Web of Science ®Google Scholar
• Borison H L. Site of emetic action of radiation therapy in the cat. J Comp Neurol 1957; 107: 439–453
   PubMed Web of Science ®Google Scholar
• Chinn H I, Wang S C. Locus of emetic action following irradiation. Proc Soc Exp Biol Med 1954; 85: 472–474
   PubMed Web of Science ®Google Scholar
• Morrow G R, Arseneau J C, Asbury R F, et al. Anticipatory nausea and vomiting with chemotherapy. N Engl J Med 1982; 306: 431–432
   PubMed Web of Science ®Google Scholar
• Wilcox P M, Fetting J H, Nettesheim K M, et al. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 1982; 66: 1601–1604
   PubMedGoogle Scholar
• Morrow G R, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307: 1476–1480
   PubMed Web of Science ®Google Scholar
• Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy induced emesis. Drugs 1983; 25: 35–51
   PubMed Web of Science ®Google Scholar
• Moertel C G, Reitemeier R J, Gage R P. A controlled clinical evaluation of antiemetic drugs. J Am Med Assoc 1963; 186: 116–118
   PubMed Web of Science ®Google Scholar
• Moertel C G, Reitemeier R J. Controlled clinical studies of orally administred antiemetic drugs. Gastroenterology 1969; 57: 262–268
   PubMed Web of Science ®Google Scholar
• Moertel C G, Reitemeier R J. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 1973; 3: 283–287
   Google Scholar
• Sallan S E, Cronin C M, Zelen M, et al. Antiemetics in patients receiving chemotherapy for cancer: A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302: 135–138
   PubMed Web of Science ®Google Scholar
• Gralla R J, Itri L M, Pisko S E, et al. Antiemetic efficacy of high dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905–909
   PubMed Web of Science ®Google Scholar
• Frytak S, Moertel C G, O'Fallon J R, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Ann Intern Med 1979; 91: 825–830
   PubMed Web of Science ®Google Scholar
• Jacobs A J, Deppe G, Cohen C J. A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cisplatinum. Gyn Oncol 1980; 10: 55–57
   PubMed Web of Science ®Google Scholar
• Orr L E, McKernan J F, Bloone B. Antiemetic effect of tetrahydrocannabinol. Arch Intern Med 1980; 140: 1431–1433
   PubMedGoogle Scholar
• Carr B, Pulone B, Bernard M, et al. A double-blind comparison of metoclopramide (MCP) and prochlorperazine (PCP) for cis-platinum (DDP) induced emesis. Proc Am Soc Clin Oncol 1982; 1: 66
   Google Scholar
• Moertel C G, Schutt A J, Hahn R G, et al. Oral benzquinamide in the treatment of nausea and vomiting. Clin Pharmacol Ther 1976; 18: 554–557
   Web of Science ®Google Scholar
• Higi M, Niederle N, Bierbaum W, et al. Pronounced antiemetic activity of the antipsychotic drug levopromacine (L) in patients receiving cancer chemotherapy. J Cancer Res Clin Oncol 1980; 97: 81–86
   PubMed Web of Science ®Google Scholar
• Harrington R A, Hamilton C W, Brogden R N, et al. Metoclopramide: An updated review of its pharmacological properties and clinical use. Drugs 1983; 25: 451–494
   PubMed Web of Science ®Google Scholar
• Kahn T, Elias E G, Mason G R. A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 1978; 62: 1106–1107
   PubMedGoogle Scholar
• Arnold D J, Ribiero V, Bulkin W. Metoclopramide versus prochlorperazine in the prevention of vomiting from diamminedichloroplatinum. Proc Am Soc Clin Oncol 1980; 21: 344
   Google Scholar
• Belt R J, Rhodes J, Taylor S. Antiemetic therapy for patients receiving cisdiamminedichloroplatinum (II): A randomized double-blind study comparing metoclopramide and prochlorperazine. Treatment of Cancer Chemotherapy Induced Nausea and Vomiting, D S Poster, J S Penta, S Bruno. Masson Publishing, New York 1981; 153–158
   Google Scholar
• Frytak S, Moertel C G, Eagan R T. A double blind comparison of metoclopramide and prochlorperazine as antiemetics for platinum therapy. Proc Am Soc Clin Oncol 1981; 22: 421
   Google Scholar
• Gylys J A, Doran K M, Buyniski J P. Antagonism of cisplatin induced emesis in the dog. Res Commun Chem Pathol Pharmacol 1979; 23: 61–68
   PubMedGoogle Scholar
• Gralla R J, Braun T J, Squillante A, . Metoclopramide: Initial clinical studies of high dosage regimens in cisplatin-induced emesis. Treatment of Nausea and Vomiting Induced by Cancer Chemotherapy, D S Poster, J S Penta, S Bruno, et al. Masson Publishing, New York 1981; 167–176
   Google Scholar
• Goslin R H, Garnick M B. Metoclopramide as an antiemetic in patients receiving cisplatin. Treatment of Nausea and Vomiting Induced by Cancer Chemotherapy, D S Poster, J S Penta, S Bruno. Masson Publishing, New York 1981; 159–165
   Google Scholar
• Strum S B, McDermed J E, Opfell R W, et al. Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. J Am Med Assoc 1982; 247: 2683–2686
   PubMed Web of Science ®Google Scholar
• Homesley H D, Gainey J M, Jobson V N, et al. Double-blind placebo-controlled study of metoclopramide in cisplatin induced emesis. N Engl J Med 1982; 307: 250–251
   Google Scholar
• Gralla R J, Tyson L B, Bordin L A, et al. Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 1984; 68: 163–172
   PubMedGoogle Scholar
• Tyson L B, Clark R A, Gralla R J. High-dose metoclopramide: Control of dacarbazine-induced emesis in a preliminary trial. Cancer Treat Rep 1982; 66: 2108
   PubMedGoogle Scholar
• Frustaci S, Tumolo S, Tirell U, et al. High dose metoclopramide versus dexamethasone in the prevention of cisplatin induced vomiting. Proc Am Soc Clin Oncol 1983; 2: 87
   Google Scholar
• Gralla R J, Tyson L B, Clark R A, et al. Antiemetic trials with high dose metoclopramide: Superiority over THC and preservation of efficacy in subsequent chemotherapy courses. Proc Am Soc Clin Oncol 1982; 1: 58
   Google Scholar
• Garnick M B. Oral metoclopramide and cisplatin chemotherapy. Ann Intern Med 1983; 99: 127
   PubMed Web of Science ®Google Scholar
• Tyson L B, Gralla R J, Clark R A, et al. High dose oral metoclopramide: Dose finding, efficacy and preliminary pharmacokinetic evaluation. Proc Am Soc Clin Oncol 1984; 3: 102
   Google Scholar
• Kris M G, Tyson L B, Gralla R J, et al. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 1983; 309: 433
   PubMed Web of Science ®Google Scholar
• Gralla R J. Metoclopramide: a review of antiemetic trials. Drugs 1983; 25(1)63–73
   PubMedGoogle Scholar
• Strum S B, McDermed J E. Treatment of side effects in patients receiving IV Metoclopramide. Cancer Treat Rep 1983; 67: 1049–1050
   PubMedGoogle Scholar
• Meyer B, Lewin M, Drayer M, et al. Optimizing metoclopramide control of cw-platinum induced emesis. Proc Ann Intern Med 1984; 100: 393–395
   PubMed Web of Science ®Google Scholar
• Sallan S E, Zinberg N E, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795–797
   PubMed Web of Science ®Google Scholar
• Lucas V S, Laszlo J. Delta-9-tetrahydrocannabinol for refractory vomiting induced by chemotherapy. J Am Med Assoc 1980; 243: 1241–1243
   PubMed Web of Science ®Google Scholar
• Chang A E, Shiling D J, Stillman R C, et al. Delta-9-tetrahydrocannabinol as an antiemetic in patients receiving high-dose methotrexate: A prospective, randomized evaluation. Ann Intern Med 1979; 91: 819–824
   PubMed Web of Science ®Google Scholar
• Chang A E, Shiling D J, Stillman R C, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and Cytoxan chemotherapy. Cancer 1981; 47: 1746–1751
   PubMed Web of Science ®Google Scholar
• Carey M P, Burish T G, Brenner D E. Delta-9-tetrahydrocan-nabinol in cancer chemotherapy: Research problems and issues. Ann Intern Med 1983; 99: 106–114
   PubMed Web of Science ®Google Scholar
• Herman T S, Einhorn L H, Jones S E, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300: 1295–1297
   PubMed Web of Science ®Google Scholar
• Steele N, Gralla R J, Braun D W, et al. Double blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980; 64: 219–224
   PubMedGoogle Scholar
• Vincent B J, McQuiston D J, Einhom L H, et al. Review of cannabinoids and their antiemetic effectiveness. Drugs 1983; 25(Suppl 1)52–62
   PubMedGoogle Scholar
• Rich W M, Abdulhaygul G, Disaia P J. Methylprednisolone as an antiemetic during cancer chemotherapy—A pilot study. Gynecol Oncol 1980; 9: 193–198
   PubMed Web of Science ®Google Scholar
• Lee B J. Methylprednisolone as an antiemetic. N Engl J Med 1981; 303: 486
   Google Scholar
• Aapro M S, Plexia P M, Alberts D S, et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone vs high-dose metoclopramide. Proc Am Soc Clin Oncol 1983; 2: 93
   Google Scholar
• Cassileth P A, Lusk E J, Torri S, et al. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 1983; 143: 1347–1349
   PubMed Web of Science ®Google Scholar
• McDermed J E. A randomized, cross-over comparison of the effectiveness of intravenous (IV) metoclopramide and IV dexamethasone as antiemetic prevention in cancer chemotherapy. Proc Am Soc Clin Oncol 1983; 2: 89
   Google Scholar
• Aapro M S, Alberts D S. High-dose dexamethasone for prevention of m-platinum induced vomiting. Cancer Chemother Pharmacol 1981; 7: 11–14
   PubMed Web of Science ®Google Scholar
• Mason B A, Dambra J, Grossman B, et al. Effective control of cisplatin-induced nausea using high-dose steroids and droperidol. Cancer Treat Rep 1982; 66: 243–245
   PubMedGoogle Scholar
• Miller C, Bernton E, Marshall S, et al. Dexamethasone anti-emesis study: A double-blind clinical trial. Proc Am Soc Clin Oncol 1982; 1: 64
   Google Scholar
• Tyson L B, Gralla R J, Clark R A, et al. Combination antiemetic trials with metoclopramide. Proc Am Soc Clin Oncol 1983; 2: 91
   Google Scholar
• Zamkoff K, Kirshner J, Cass D, et al. Adrenal response to serial cosyntropin stimulation after repeated high-dose prednisone administration in patients with lymphoma. Cancer Treat Rep 1981; 65: 563–566
   PubMedGoogle Scholar
• Shields K G, Ballinger C M, Hathaway B N. Antiemetic effectiveness of haloperidol in human volunteers challenged with apomorphine. Anesthesiol Analges 1971; 50: 1017–1024
   PubMed Web of Science ®Google Scholar
• Tornetta F J. Double-blind evaluation of haloperidol for antiemetic activity. Anesthesiol Analges 1972; 51: 964–967
   PubMed Web of Science ®Google Scholar
• Patton C M, Moon M R, Dannemiller F J. The prophylactic antiemetic effect of droperidol. Anesthesiol Analges 1974; 53: 361–364
   PubMed Web of Science ®Google Scholar
• Grossman B, Lessin L S, Cohen P. Droperidol prevents nausea and vomiting from m-platinum. N Eng J Med 1979; 301: 47
   PubMed Web of Science ®Google Scholar
• Wilson J, Weltz M, Solimando D, et al. Continuous infusion droperidol: Antiemetic therapy for cisplatinum toxicity. Proc Am Soc Clin Oncol 1981; 22: 421
   Google Scholar
• Neidhart J A, Gagen M, Young D, et al. Specific antiemetics for specific cancer chemotherapeutic agents: Haloperidol vs. benzquinamide. Cancer 1981; 47: 1439–1443
   PubMed Web of Science ®Google Scholar
• Grunberg S M, Gala K V, Lampenfeld M, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haldol in a randomized double-blind crossover study. J Clin Oncol 1984; 2: 782–787
   PubMed Web of Science ®Google Scholar
• Plotkin D A, Plotkin D, Okun R. Haloperidol in the treatment of nausea and vomiting due to cytotoxic drug administration. Curr Ther Res 1973; 15: 599–602
   PubMed Web of Science ®Google Scholar
• Laszo J, Hanson D C, Lucas V S, et al. Lorazepam as an antiemetic against cisplatin. Proc Am Soc Clin Oncol 1983; 2: 95
   Google Scholar
• Meyer M, Long A M, Natale R B, et al. Phase I, II and III trials of a new antiemetic agent-lorazepam. Proc Am Soc Clin Oncol 1983; 2: 88
   Google Scholar
• Robins I H, Erschler N G, Dejongh L. Antiemetic effect of intravenous diazepam in patients receiving cis-diamminedichloroplatinum (II): A pilot study. Med Pediatr Oncol 1979; 7: 247–249
   PubMedGoogle Scholar
• Plezia P M, Alberts D S, Aapro M S, et al. Immediate termination of intractable cisplatin induced vomiting with an intensive 5-drug antiemetic regimen. Proc Am Soc Clin Oncol 1983; 2: 93
   Google Scholar
• Lane R, McGee R, Rivkin S. Antiemetic combination (BCDVR) for control of platinum induced emesis. Proc Am Soc Clin Oncol 1982; 1: 65
   Google Scholar
• Friedlander M L, Kearsley J H, Sims K, et al. Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. Austr NZ J Med 1983; 13: 53–56
   PubMedGoogle Scholar
• Kris M G, Gralla R J, Tyson L B, et al. Improved control of cisplatin-induced emesis with high dose metoclopramide and with combinations of metoclopramide dexamethasone and diphenhydramine: Results of consecutive trials in 255 patients. Cancer, in press
   Google Scholar
• Homesley H D, Gainey J, Jobson V W, et al. Failure of delta-9-tetrahydrocannabinol and prochlorperazine to control chemotherapy induced nausea and vomiting. Proc Am Soc Clin Oncol 1982; 1: 67
   Google Scholar
• Artim R, Dibella N. Tetrahydrocannabinol plus prochlorperazine for refractory nausea and vomiting. Proc Am Soc Clin Oncol 1983; 2: 85
   Google Scholar
• Peroutka S, Snyder S. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; 1: 658–659
   PubMed Web of Science ®Google Scholar